HHS Secretary Azar Comments on Drug Industry Price Transparency Announcement

16. October 2018 EHR, EMR, Health, HIPAA 0

Health and Human Services Secretary Alex Azar issued the following statement regarding pharmaceutical companies’ announcement that they would be providing access to more information on drug prices:

“Patient empowerment and transparency are at the core of the President’s drug-pricing blueprint that was released five months ago. Our vision for a new, more transparent drug-pricing system does not rely on voluntary action. The drug industry remains resistant to providing real transparency around their prices, including the sky-high list prices that many patients pay. So while the pharmaceutical industry’s action today is a small step in the right direction, we will go further and continue to implement the President’s blueprint to deliver new transparency and put American patients first. “ 

Powered by WPeMatico